Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy
NCT02501551
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
36
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Interventions
DRUG:
regorafenib
Sponsor
Yonsei University